Pharmacogenomics and health disparities, are we helping?

Shaaban, Sherin; Yuan, Jian

doi:10.3389/fgene.2023.1099541

Cited by 3 publications

(2 citation statements)

References 139 publications

(145 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SNP analysis and pharmacogenetic‐based opiate prescribing offers a much more precise and biologically driven approach which could reduce the racial and ethnic bias in opiate prescribing practices 12‐16 . Evidence of the impact of different SNP's in opiate drug response is growing.…”

Section: Figurementioning

confidence: 99%

Pharmacogenetics: Using science to reduce racial bias in pain management?

Austin,

Sanderson,

Crona

et al. 2023

J American Geriatrics Society

View full text Add to dashboard Cite

Section: Figurementioning

confidence: 99%

Pharmacogenetics: Using science to reduce racial bias in pain management?

Austin,

Sanderson,

Crona

et al. 2023

J American Geriatrics Society

View full text Add to dashboard Cite

“…In pharmacogenomics, the study of how individual genetic variations influence drug responses has led to personalized drug prescriptions, minimizing adverse drug reactions, and improving treatment efficacy. Existing health disparities, as they intersect pharmacogenomic research and implementation, are being identified [ 21 ].…”

Section: Precision Medicine and Public Healthmentioning

confidence: 99%

Advancing Precision Medicine in South Tyrol, Italy: A Public Health Development Proposal for a Bilingual, Autonomous Province

Wiedermann¹

2023

JPM

View full text Add to dashboard Cite

This paper presents a comprehensive development plan for advancing precision medicine in the autonomous province of South Tyrol, Italy, a region characterized by its bilingual population and unique healthcare challenges. This study highlights the need to address the shortage of healthcare professionals proficient in language for person-centered medicine, the lag in healthcare sector digitalization, and the absence of a local medical university, all within the context of an initiated pharmacogenomics program and a population-based precision medicine study known as the “Cooperative Health Research in South Tyrol” (CHRIS) study. The key strategies for addressing these challenges and integrating CHRIS study findings into a broader precision medicine development plan are discussed, including workforce development and training, investment in digital infrastructure, enhanced data management and analytic capabilities, collaboration with external academic and research institutions, education and capacity building, securing funding and resources, and promoting a patient-centered approach. This study emphasizes the potential benefits of implementing such a comprehensive development plan, including improved early detection, personal ized treatment, and prevention of chronic diseases, ultimately leading to better healthcare outcomes and overall well-being in the South Tyrolean population.

show abstract

Utilization and associated factors of TPMT testing among Australian adults receiving thiopurines: A national retrospective data‐linkage study

Yiu,

Ianni,

Fujita

et al. 2024

Pharmacotherapy

View full text Add to dashboard Cite

IntroductionThiopurine drugs are metabolized by thiopurine methyltransferase (TPMT) and low TPMT activity can result in severe adverse drug reactions. Therefore, TPMT testing is recommended for individuals receiving thiopurines to reduce the risk of toxicity.ObjectivesThe objectives of this study were to assess the rate of TPMT testing among individuals receiving thiopurines and explore factors associated with undergoing TPMT testing in Australia.MethodsThis retrospective cohort study utilized administrative data from the Pharmaceutical Benefits Scheme (PBS), Medicare Benefits Schedule (MBS), and the 2021 Census, accessed via the Person Level Integrated Data Asset (PLIDA) at the Australian Bureau of Statistics (ABS) DataLab. Individuals receiving thiopurines aged 18 years or above were identified using PBS data and exposure to TPMT testing was determined using MBS data. Multivariate logistic regression was performed to identify factors associated with TPMT testing.ResultsA total of 62,574 prevalent thiopurine users were identified between 2020 and 2022. Of these, 20,327 (32.5%) underwent TPMT testing (2011–2022). The most significant factor associated with TPMT testing was having at least one thiopurine medication prescribed by a medical specialist (adjusted odds ratio [aOR] 2.12, 95% confidence interval [CI] 2.02–2.22), compared to having medication solely prescribed by primary care physicians (PCPs). Other significant factors associated with TPMT testing included speaking a non‐English language at home (aOR 1.29, 95% CI 1.22–1.36), having no chronic health conditions (aOR 1.18, 95% CI 1.13–1.24), not requiring assistance with core activities (aOR 1.16, 95% CI 1.08–1.23), and having a higher educational attainment (aOR 1.11, 95% CI 1.06–1.11). Compared to living in major cities, individuals living in remote areas were significantly less likely to undergo testing (aOR 0.49, 95% CI 0.39–0.60).ConclusionOur study highlights the low utilization of TPMT testing in Australia and suggests the need for targeted interventions to address disparities and improve TPMT testing.

show abstract

Pharmacogenomics and health disparities, are we helping?

Cited by 3 publications

References 139 publications

Pharmacogenetics: Using science to reduce racial bias in pain management?

Pharmacogenetics: Using science to reduce racial bias in pain management?

Advancing Precision Medicine in South Tyrol, Italy: A Public Health Development Proposal for a Bilingual, Autonomous Province

Utilization and associated factors of TPMT testing among Australian adults receiving thiopurines: A national retrospective data‐linkage study

Contact Info

Product

Resources

About